| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-117 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司 关于实施 2025 年半年度权益分派调整可转债 转股价格暨转股复牌的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券停复牌情况：适用 因实施 2025 年半年度权益分派，上海皓元医药股份有限公司（以下简称"公 司"）的相关证券停复牌情况如下：权益分派实施公告披露日前一交易日（2025 年 10 月 13 日）至权益分派股权登记日（2025 年 10 月 21 日）期间，本公司可转 债将停止转股，2025 年 10 月 22 日起恢复转股。 | 证券代码 | 证券简称 | 停复牌类 | 停牌起 | 停牌期 | 停牌终止日 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | | | | 型 | 始日 | 间 | | | | 118051 | 皓 ...

| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-115 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司 关于调整 2025 年半年度利润分配现金分红 总额的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 现金分红总额调整情况：上海皓元医药股份有限公司（以下简称"公 司"）2025 年半年度拟向全体股东每 10 股派发现金红利 0.80 元（含税）维持不 变，派发现金红利总额由 16,967,901.20 元（含税）调整为 16,967,993.52 元（含 税）。 本次调整原因：因公司公开发行的"皓元转债"目前处于转股期内，导 致公司实际参与利润分配的股份数量增加，公司拟维持每股分配金额不变，相 应调整 2025 年半年度现金分配总额。 一、调整前利润分配方案 根据公司 2024 年年度股东大会的授权，公司分别于 2025 年 8 月 26 日召开 第四届董事会审计委员会第五次会议、2025 ...

| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-116 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司 2025年半年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/10/21 | 2025/10/22 | 2025/10/22 | 一、 通过分配方案的股东会届次和日期 本次利润分配方案经公司2025 年 4 月 18 日的2024年年度股东大会授权公司董 事会制定，并经公司 2025 年 8 月 27 日召开的第四届董事会第十一次会议审议通 过后实施。 二、 分配方案 1. 发放年度：2025年半年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 1 是 ...

Group 1 - The core point of the article highlights the recent decline in the stock price of Haoyuan Pharmaceutical, which fell by 5.05% to 76.91 CNY per share, with a trading volume of 178 million CNY and a turnover rate of 1.07%, resulting in a total market capitalization of 16.313 billion CNY [1] - Haoyuan Pharmaceutical, established on September 30, 2006, and listed on June 8, 2021, specializes in the discovery of small molecule drugs, including the development of molecular building blocks and tool compounds, as well as the process development and production technology improvement of active pharmaceutical ingredients (APIs) and intermediates [1] - The company's main business revenue composition includes 68.97% from molecular building blocks, tool compounds, and biochemical reagents, with product sales accounting for 63.42%, APIs and intermediates contributing 30.46%, and technical services making up 5.55% [1] Group 2 - From the perspective of fund holdings, Haoyuan Pharmaceutical is a significant position in the Hongta Hongtu Fund, specifically in the Hongta Hongtu Medical Selected Stock A Fund (020331), which holds 13,000 shares, representing 4.93% of the fund's net value, ranking as the fourth-largest holding [2] - The Hongta Hongtu Medical Selected Stock A Fund (020331) was established on April 2, 2024, with a latest scale of 11.6663 million CNY, achieving a year-to-date return of 32.35%, ranking 1626 out of 4220 in its category, and a one-year return of 20.3%, ranking 2324 out of 3855 [2]

| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-114 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 具体变动情况如下： 1 上海皓元医药股份有限公司 关于控股股东可转债持有比例变动达到 10%的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、可转债配售情况 经中国证券监督管理委员会《关于同意上海皓元医药股份有限公司向不特 定对象发行可转换公司债券注册的批复》（证监许可[2024]1289 号）同意，上海 皓元医药股份有限公司（以下简称"公司"、"本公司"）于 2024 年 11 月 28 日 向不特定对象发行 822.35 万张可转换公司债券，每张面值为人民币 100 元，发 行总额 82,235.00 万元，期限 6 年。 经上海证券交易所自律监管决定书[2024]168 号文同意，公司本次可转换公 司债券于 2024 年 12 月 19 日起在上海证券交易所上市交易，债券简称"皓元转 债"，债券代码"118051"。 公司 ...

Group 1 - The core point of the news is that Haoyuan Pharmaceutical's stock price dropped by 5.24% to 81.00 CNY per share, with a trading volume of 237 million CNY and a turnover rate of 1.35%, resulting in a total market capitalization of 17.18 billion CNY [1] - Haoyuan Pharmaceutical, established on September 30, 2006, and listed on June 8, 2021, specializes in the discovery of small molecule drugs, including the research and development of molecular building blocks and tool compounds, as well as the process development and production technology improvement of active pharmaceutical ingredients and intermediates [1] - The company's main business revenue composition includes molecular building blocks, tool compounds, and biochemical reagents at 68.97%, with product sales contributing 63.42%, active pharmaceutical ingredients and intermediates at 30.46%, technical services at 5.55%, and other supplementary services at 0.57% [1] Group 2 - From the perspective of fund holdings, Haoyuan Pharmaceutical is a top ten holding of the Hengsheng Qianhai Fund, specifically in the Hengsheng Qianhai Hong Kong-Shenzhen Emerging Industry Selected Mixed Fund (004332), which held 24,600 shares, accounting for 2.1% of the fund's net value, with an estimated floating loss of approximately 110,200 CNY [2] - The Hengsheng Qianhai Hong Kong-Shenzhen Emerging Industry Selected Mixed Fund (004332) was established on April 1, 2017, with a latest scale of 56.68 million CNY, achieving a year-to-date return of 43.74% and a one-year return of 40.63% [2] - The fund manager, Xing Cheng, has been in position for 3 years and 203 days, with the fund's total asset size at 252 million CNY, achieving the best return of 87.69% and the worst return of -29.15% during his tenure [3]

Core Viewpoint - The performance of the Zhongzheng 1000 ETF Enhanced (561280) has shown a slight decline at the opening, with a reported drop of 0.33% to 1.517 yuan, indicating market volatility and investor sentiment towards the fund's holdings [1] Group 1: Fund Performance - The Zhongzheng 1000 ETF Enhanced (561280) has a performance benchmark based on the Zhongzheng 1000 Index return [1] - Since its establishment on August 31, 2023, the fund has achieved a return of 52.12% [1] - Over the past month, the fund has recorded a return of 5.46% [1] Group 2: Major Holdings - Key stocks in the fund include Xiangdian Co., which opened down 0.55%, and Haoyuan Pharmaceutical, which fell by 1.15% [1] - Other notable stocks include Xinqianglian, which rose by 0.43%, and Chujian New Materials, which increased by 0.40% [1] - The fund also holds shares in Nanwei Software, Zhenlei Technology, and Hongsoft Technology, with varying performance [1]

Core Insights - On October 9, Haoyuan Pharmaceutical's stock rose by 3.49%, with a trading volume of 508 million yuan [1] - The company reported a financing buy-in of 70.22 million yuan and a net financing buy-in of 3.93 million yuan on the same day [1] - As of October 9, the total balance of margin trading for Haoyuan Pharmaceutical was 416 million yuan, indicating a high level of trading activity [1] Financing Summary - On October 9, Haoyuan Pharmaceutical had a financing buy-in of 70.22 million yuan, with a current financing balance of 414 million yuan, representing 2.29% of its market capitalization [1] - The financing balance is above the 90th percentile of the past year, indicating a high level of investor interest [1] Short Selling Summary - On October 9, Haoyuan Pharmaceutical repaid 4,660 shares in short selling and sold 3,000 shares, amounting to 256,400 yuan at the closing price [1] - The remaining short selling volume was 15,000 shares, with a short selling balance of 1.28 million yuan, which is above the 70th percentile of the past year [1] Company Overview - Haoyuan Pharmaceutical, established on September 30, 2006, is located in Shanghai and specializes in the discovery of small molecule drugs, including the development of molecular building blocks and tool compounds [2] - The company's main business revenue composition includes 68.97% from molecular building blocks, tool compounds, and biochemical reagents, with product sales contributing 63.42% [2] - As of September 19, the number of shareholders increased by 17.93% to 12,800, with an average of 16,527 circulating shares per person, a decrease of 12.82% [2] Financial Performance - For the first half of 2025, Haoyuan Pharmaceutical achieved a revenue of 1.311 billion yuan, representing a year-on-year growth of 24.20% [2] - The net profit attributable to shareholders was 152 million yuan, showing a significant year-on-year increase of 115.55% [2] Dividend Information - Since its A-share listing, Haoyuan Pharmaceutical has distributed a total of 143 million yuan in dividends, with 103 million yuan distributed over the past three years [3] Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited was the fourth largest circulating shareholder, holding 6.2611 million shares, an increase of 329,200 shares from the previous period [3] - The fund "China Europe Medical Health Mixed A" ranked fifth among circulating shareholders, holding 6.1185 million shares, a decrease of 2.7776 million shares from the previous period [3]

Core Points - The announcement details the conversion results of the convertible bonds issued by Shanghai Haoyuan Pharmaceutical Co., Ltd. and the changes in share capital as of September 30, 2025 [1][2] Group 1: Convertible Bond Conversion Status - As of September 30, 2025, a total of RMB 464,000 of "Haoyuan Convertible Bonds" has been converted into company shares, resulting in 11,412 shares, which accounts for 0.0054% of the total shares before conversion [2][6] - The amount of "Haoyuan Convertible Bonds" that has not been converted as of September 30, 2025, is RMB 821,886,000, representing 99.94% of the total issuance [2][6] - During the period from July 1, 2025, to September 30, 2025, RMB 414,000 of "Haoyuan Convertible Bonds" was converted into shares, totaling 10,190 shares, which is 0.0048% of the total shares before conversion [2][6] Group 2: Convertible Bond Issuance Overview - The company issued 8,223,500 convertible bonds on November 28, 2024, with a total value of RMB 82,235,000 and a maturity of 6 years [3] - The bonds were listed for trading on December 19, 2024, under the name "Haoyuan Convertible Bonds" with the code "118051" [3] - The initial conversion price was set at RMB 40.73 per share, with adjustments made due to various corporate actions [3][4][5] Group 3: Share Capital Changes - The total share capital of the company was reduced by 47,725 shares on July 4, 2025, due to the cancellation of shares related to performance commitments [7] - The company completed the registration of 648,570 shares from the 2022 restricted stock incentive plan on July 8, 2025, which were then listed for trading [8] - Additional shares from the 2023 restricted stock incentive plan were also registered and listed for trading in subsequent months [8]

Market Overview - On October 9, the medical services sector rose by 0.91%, with Jiuzhou Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3933.97, up 1.32%, while the Shenzhen Component Index closed at 13725.56, up 1.47% [1] Top Gainers in Medical Services - Jiuzhou Pharmaceutical (603456) closed at 20.61, up 5.96% with a trading volume of 418,800 shares and a transaction value of 844 million [1] - Meinian Health (002044) closed at 5.20, up 4.63% with a trading volume of 1,667,200 shares and a transaction value of 871 million [1] - Heyuan Biotechnology (688238) closed at 8.20, up 4.19% with a trading volume of 344,500 shares and a transaction value of 285 million [1] - Sanbo Brain Science (301293) closed at 60.80, up 4.02% with a trading volume of 110,100 shares and a transaction value of 660 million [1] - Haoyuan Pharmaceutical (688131) closed at 85.48, up 3.49% with a trading volume of 59,800 shares and a transaction value of 508 million [1] Top Losers in Medical Services - Digital Human (920670) closed at 14.21, down 8.73% with a trading volume of 68,800 shares and a transaction value of 96.92 million [2] - ST Biological (000504) closed at 9.07, down 4.02% with a trading volume of 46,100 shares and a transaction value of 42.42 million [2] - Baicheng Pharmaceutical (301096) closed at 57.99, down 3.35% with a trading volume of 32,600 shares and a transaction value of 191 million [2] Fund Flow Analysis - The medical services sector experienced a net outflow of 308 million from institutional investors, while retail investors saw a net inflow of 348 million [2] - The net outflow from retail investors amounted to 40.85 million [2] Individual Stock Fund Flow - Aier Eye Hospital (300015) had a net inflow of 283 million from institutional investors, while retail investors experienced a net outflow of 137 million [3] - Sanbo Brain Science (301293) saw a net inflow of 63.69 million from institutional investors, with retail investors facing a net outflow of 45.84 million [3] - Jiuzhou Pharmaceutical (603456) had a net inflow of 53.54 million from institutional investors, while retail investors faced a net outflow of 63.40 million [3]